Drug Trial Radar · NCT06485401
To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Mar 14, 2024
Primary completion
Jun 21, 2024
Study completion Jun 21, 2024
Sponsor
- Lead sponsor
- Jiaxing AnDiCon Biotech Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of ADC189 in subjects with hepatic impairment compared with subjects with normal hepatic function.
Conditions
- Influenza Type A
- Influenza Type B
Interventions
ADC189Drug
45 mg per tablet, oral administration, single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of ADC189/ADC189-I07Time frame: 15 days
- AUClast of ADC189/ADC189-I07Time frame: 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.